Company Overview of Sandoz Inc.
Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...
100 College Road West
Princeton, NJ 08540
Founded in 1946
Key Executives for Sandoz Inc.
President and Head of North America
Chief Financial Officer, Head of Finance - North America and Vice President
President of Oriel Therapeutics
Vice President of Legal, IP & Compliance and General Counsel of NA
Head of Global Development Biopharmaceuticals & Oncology Injectables
Compensation as of Fiscal Year 2015.
Sandoz Inc. Key Developments
The Medicines Company Announces Distribution Agreement with Sandoz in US
Jul 17 15
The Medicines Company has signed an agreement with Sandoz Inc. for the distribution of an authorized generic of its anticoagulant, ANGIOMAX, or bivalirudin, for injection, in the US. This agreement with Sandoz, itself a leader in the generics market, helps to ensure that bivalirudin remains a high quality product in this market.
The Medicines Co. Announces Distribution Agreement with Sandoz Inc
Jul 9 15
The Medicines Co. announced an agreement with Sandoz Inc. for the distribution of an authorized generic of Angiomax (bivalirudin) for injection in the U.S. Angiomax is indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of GPI and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. Also, Angiomax is indicated for use as an anticoagulant in patients with UA undergoing percutaneous transluminal coronary angioplasty.
Sandoz Launches Attention Deficit Hyperactivity Disorder Drug in US
Jun 18 15
Sandoz has launched guanfacine hydrochloride extended release tablets indicated for the treatment of attention deficit hyperactivity disorder, or ADHD, in the US. Guanfacine hydrochloride extended release tablets is a generic version of INTUNIV, which is currently marketed by Shire Pharmaceuticals. Guanfacine hydrochloride extended release is a central alpha2A-adrenergic receptor agonist indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 26, 2015